IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer

NCT07377643 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

540

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2-positive Breast Cancer

Interventions

DRUG: Trastuzumab
DRUG: IBI354
DRUG: Docetaxel
DRUG: Pertuzumab
DRUG: Paclitaxel

Sponsor

Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.